Up-regulation of CYP expression in hepatoma cells stably transfected by chimeric nuclear receptors

European Journal of Pharmaceutical Sciences

Volumn 40, Issue 4, 2010, Pages 263-272

  Küblbeck, Jenni ^a   Reinisalo, Mika ^a   Mustonen, Riitta ^a   Honkakoski, Paavo ^a  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

CAR; CYP3A4; Cytochrome P450; Drug metabolism; Nuclear receptor; PXR

Indexed keywords

CELL NUCLEUS RECEPTOR; CONSTITUTIVE ANDROSTANE RECEPTOR; CYTOCHROME P450; CYTOCHROME P450 2B6; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; GENOMIC DNA; MESSENGER RNA; PREGNANE X RECEPTOR; TRANSCRIPTION FACTOR RELA; CELL RECEPTOR; COREPRESSOR PROTEIN; CYP2B6 PROTEIN, HUMAN; CYP2C9 PROTEIN, HUMAN; CYP3A4 PROTEIN, HUMAN; CYTOCHROME P450 3A; HYBRID PROTEIN; N DEMETHYLASE; NUCLEAR RECEPTOR COACTIVATOR; RELA PROTEIN, HUMAN; STEROID RECEPTOR; UNSPECIFIC MONOOXYGENASE; XENOBIOTIC AGENT;

AMINO TERMINAL SEQUENCE; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL STRAIN HEPG2; CONTROLLED STUDY; GENE DOSAGE; GENETIC TRANSFECTION; HEPATOMA CELL; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; MOLECULAR CLONING; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPORTER GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; WILD TYPE; COMPARATIVE STUDY; GENETICS; HEPG2 CELL LINE; LIVER; LIVER CELL CARCINOMA; METABOLISM; PROTEIN DOMAIN; TRANSCRIPTION INITIATION; TUMOR CELL LINE;

ARYL HYDROCARBON HYDROXYLASES; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CO-REPRESSOR PROTEINS; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; GENES, REPORTER; HEP G2 CELLS; HUMANS; LIVER; NUCLEAR RECEPTOR COACTIVATORS; OXIDOREDUCTASES, N-DEMETHYLATING; PROTEIN INTERACTION DOMAINS AND MOTIFS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, STEROID; RECOMBINANT FUSION PROTEINS; RNA, MESSENGER; TRANSCRIPTION FACTOR RELA; TRANSCRIPTIONAL ACTIVATION; UP-REGULATION; XENOBIOTICS; CYTOCHROME P-450 CYP2B6; CYTOCHROME P-450 CYP2C9;

EID: 77953544986     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2010.03.022     Document Type: Article

References (67)

1. Akiyama T.E., Gonzalez F.J. Regulation of P450 genes by liver-enriched transcription factors and nuclear receptors. Biochim. Biophys. Acta 2003, 1619:223-234.
2. Abruzzese R.V., Godin D., Mehta V., Perrard J.L., French M., Nelson W., Howell G., Coleman M., O'Malley B.W., Nordstrom J.L. Ligand-dependent regulation of vascular endothelial growth factor and erythropoietin expression by a plasmid-based autoinducible GeneSwitch system. Mol. Ther. 2000, 2:276-287.
3. Aninat C., Piton A., Glaise D., Le Charpentier T., Langouet S., Morel F., Guguen-Guillouzo C., Guillouzo A. Expression of cytochromes P450, conjugating enzymes and nuclear receptors in human hepatoma HepaRG cells. Drug. Metab. Dispos. 2006, 34:75-83.
4. Burcin M.M., Schiedner G., Kochanek S., Tsai S.Y., O'Malley B.W. Adenovirus-mediated regulatatble target gene expression in vivo. Proc. Natl. Acad. Sci. USA 1999, 96:355-360.
5. Butura A., Johansson I., Nilsson K., Wärngård L., Ingelman-Sundberg M., Schuppe-Koistinen I. Differentiation of human hepatoma cells during confluence as revealed by gene expression profiling. Biochem. Pharmacol. 2004, 67:1249-1258.
6. Bustin S.A. Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays. J. Mol. Endocrinol. 2000, 25:169-193.
7. Bustin S.A. Quantification of mRNA using real-time reverse transcription PCR (RT-PCR): trends and problems. J. Mol. Endocrinol. 2002, 29:23-39.
8. Castell J.V., Jover R., Martínez-Jiménez C.P., Gómez-Lechón M.J. Hepatocyte cell lines: their use, scope and limitations in drug metabolism studies. Expert Opin. Drug Metab. Toxicol. 2006, 2:183-212.
9. Chang T.K., Bandeira S.M., Chen J. Constitutive androstane receptor and pregnane X receptor gene expression in human liver: interindividual variability and correlation with CYP2B6 mRNA levels. Drug Metab. Dispos. 2003, 31:7-10.
10. Donato M.T., Jimenez N., Castell J.V., Gomez-Lechon M.J. Fluorescence-based assays for screening nine cytochrome P450 (P450) activities in intact cells expressing individual human P450 enzymes. Drug Metab. Dispos. 2004, 32:699-706.
11. Donato M.T., Lahoz A., Castell J.V., Gómez-Lechón M.J. Cell lines: a tool for in vitro drug metabolism studies. Curr. Drug Metab. 2008, 9:1-11.
12. Elizondo G., Medina-Diaz I.M. Induction of CYP3A4 by 1α,25-dihydroxyvitamin D3 in HepG2 cells. Life Sci. 2003, 73:141-149.
13. Elkayam T., Amitay-Shaprut S., Dvir-Ginzberg M., Harel T., Cohen S. Enhancing the drug metabolism activities of C3A - a human hepatocyte cell line - by tissue engineering within alginate scaffolds. Tissue Eng. 2006, 12:1357-1368.
14. Fan X., Roy E., Zhu L., Murphy T.C., Kozlowski M., Nanes M.S., Rubin J. Nitric oxide donors inhibit luciferase expression in a promoter-independent fashion. J. Biol. Chem. 2003, 278:10232-10238.
15. Germain P., Staels B., Dacquet C., Spedding M., Laudet V. Overview of nomenclature of nuclear receptors. Pharmacol. Rev. 2006, 58:685-704.
16. Gómez-Lechón M.J., Donato T., Jover R., Rodriguez C., Ponsoda X., Glaise D., Castell J.V., Guguen-Guillouzo C. Expression and induction of a large set of drug-metabolizing enzymes by the highly differentiated human hepatoma cell line BC2. Eur. J. Biochem. 2001, 268:1448-1459.
17. Goodwin B., Hodgson E., Liddle C. The orphan human pregnane X receptor mediates the transcriptional activation of CYP3A4 by rifampicin through a distal enhancer module. Mol. Pharmacol. 1999, 56:1329-1339.
18. Goodwin B., Hodgson E., D'Costa D.J., Robertson G.R., Liddle C. Transcriptional regulation of the human CYP3A4 gene by the constitutive androstane receptor. Mol. Pharmacol. 2002, 62:359-365.
19. Guillouzo A., Corlu A., Aninat C., Glaise D., Morel F., Guguen-Guillouzo C. The human hepatoma HepaRG: a highly differentiated model for studies of liver metabolism and toxicity of xenobiotics. Chem. Biol. Interact. 2007, 168:217-222.
20. Handschin C., Meyer U.A. Induction of drug metabolism: the role of nuclear receptors. Pharmacol. Rev. 2003, 55:649-673.
21. Hewitt N.J., Hewitt P. Phase I and II enzyme characterization of two sources of HepG2 cell lines. Xenobiotica 2004, 34:243-256.
22. Hewitt N.J., LeCluyse E.L., Ferguson S.S. Induction of hepatic cytochrome P450 enzymes: methods, mechanisms, recommendations, and in vitro-in vivo correlations. Xenobiotica 2007, 37:1196-1224.
23. Honkakoski P. Nuclear receptors CAR and PXR in metabolism and elimination of drugs. Curr. Pharmacogenomics 2003, 1:75-85.
24. Honkakoski P., Jääskeläinen I., Kortelahti M., Urtti A. A novel drug-regulated gene expression system based on the nuclear receptor constitutive androstane receptor (CAR). Pharm. Res. 2001, 18:146-150.
25. Honkakoski P., Moore R., Washburn K.A., Negishi M. Activation by diverse xenochemicals of the 51-base pair phenobarbital-responsive enhancer module in the CYP2B10 gene. Mol. Pharmacol. 1998, 53:597-601.
26. Jiang G., Nepomuceno L., Hopkins K., Sladek F.M. Exclusive homodimerization of the orphan receptor hepatocyte nuclear factor 4 defines a new subclass of nuclear receptors. Mol. Cell. Biol. 1995, 15:5131-5143.
27. Jiang X., Takahashi N., Ando K., Otsuka T., Tetsuka T., Okamoto T. NF-kappa B p65 transactivation domain is involved in the NF-kappa B-inducing kinase pathway. Biochem. Biophys. Res. Commun. 2003, 301:583-590.
28. Johnson D.R., Li C.W., Chen L.Y., Ghosh J.C., Chen J.D. Regulation and binding of pregnane X receptor by nuclear receptor corepressor silencing mediator of retinoid and thyroid hormone receptors (SMRT). Mol. Pharmacol. 2006, 69(9):99-108.
29. Jover R., Bort R., Gomez-Lechon M.J., Castell J.V. Re-expression of C/EBP alpha induces CYP2B6, CYP2C9 and CYP2D6 genes in HepG2 cells. FEBS Lett. 1998, 431:227-230.
30. Korjamo T., Honkakoski P., Toppinen M.R., Niva S., Reinisalo M., Palmgren J.J., Mönkkönen J. Absorption properties and P-glycoprotein activity of modified Caco-2 cell lines. Eur. J. Pharm. Sci. 2005, 26:266-279.
31. Korjamo T., Mönkkönen J., Uusitalo J., Turpeinen M., Pelkonen O., Honkakoski P. Metabolic and efflux properties of Caco-2 cells stably transfected with nuclear receptors. Pharm. Res. 2006, 23:1991-2001.
32. Lamba J.K. Pharmacogenetics of the constitutive androstane receptor. Pharmacogenomics 2008, 9(1):71-83.
33. Maglich J.M., Stoltz C.M., Goodwin B., Hawkins-Brown D., Moore J.T., Kliewer S.A. Nuclear pregnane × receptor and constitutive androstane receptor regulate overlapping but distinct sets of genes involved in xenobiotic detoxification. Mol. Pharmacol. 2002, 62:638-646.
34. Maglich J.M., Parks D.J., Moore L.B., Collins J.L., Goodwin B., Billin A.N., Stoltz C.A., Kliewer S.A., Lambert M.H., Willson T.M., Moore J.T. Identification of a novel human constitutive androstane receptor (CAR) agonist and its use in the identification of CAR target genes. J. Biol. Chem. 2003, 278:17277-17283.
35. Martinez-Jimenez C.P., Gomez-Lechon M.J., Castell J.V., Jover R. Underexpressed coactivators PGC1α and SRC1 impair hepatocyte nuclear factor 4α function and promote dedifferentiation in human hepatoma cells. J. Biol. Chem. 2006, 281:29840-29849.
36. Müller P.Y., Janovjak H., Miserez A.R., Dobbie Z. Processing of gene expression data generated by quantitative real-time RT-PCR. Biotechniques 2002, 32:1372-1374.
37. Mäkinen J., Frank C., Jyrkkärinne J., Gynther J., Carlberg C., Honkakoski P. Modulation of mouse and human phenobarbital-responsive enhancer module by nuclear receptors. Mol. Pharmacol. 2002, 62:366-378.
38. Naiki T., Nagaki M., Shidoji Y., Kojima H., Moriwaki H. Functional activity of human hepatoma cells transfected with adenovirus-mediated hepatocyte nuclear factor (HNF)-4 gene. Cell Transplant. 2004, 13:393-403.
39. Nishimura M., Nobuhiko U., Naito S. Effects of dimethyl sulfoxide on the gene induction of cytochrome P450 isoforms, UGT-dependent glucuronosyl transferase isoforms, and ABCB1 in primary culture of human hepatocytes. Biol. Pharm. Bull. 2003, 26:1052-1056.
40. No D., Yao T.P., Evans R.M. Ecdysone-inducible gene expression in mammalian cells and transgenic mice. Proc. Natl. Acad. Sci. USA 1996, 93:3346-3351.
41. Ohno M., Motojima K., Okano T., Taniguchi A. Up-regulation of drug-metabolizing enzyme genes in layered co-culture of a human liver cell line and endothelial cells. Tissue Eng. Part A 2008, 14:1861-1869.
42. Pascussi J.M., Drocourt L., Gerbal-Chaloin S., Fabre J.M., Maurel P., Vilarem M.J. Dual effect of dexamethasone on CYP3A4 gene expression in human hepatocytes, sequential role of glucocorticoid receptor and pregnane X receptor. Eur. J. Biochem. 2001, 268:6346-6358.
43. Pelkonen O., Turpeinen M., Hakkola J., Honkakoski P., Hukkanen J., Raunio H. Inhibition and induction of human cytochrome P450 enzymes: current status. Arch. Toxicol. 2008, 82:667-715.
44. Pfeifer A.M., Cole K.E., Smoot D.T., Weston A., Groopman J.D., Shields P.G., Vignaud J.M., Juillerat M., Lipsky M.M., Trump B.F. Simian virus 40 large tumor antigen-immortalized normal human liver epithelial cells express hepatocyte characteristics and metabolize chemical carcinogens. Proc. Natl. Acad. Sci. USA 1993, 90:5123-5127.
45. Reinisalo M., Urtti A., Honkakoski P. Retina-specific gene expression and improved DNA transfection in WERI-Rb1 retinoblastoma cells. Biochim. Biophys. Acta 2003, 1628:169-176.
46. Rodriquez-Antona C., Donato M.T., Boobis A., Edwards R.J., Watts P.S., Castell J.V., Gómez-Lechón M.J. Cytochrome P450 expression in human hepatocytes and hepatoma cell lines: molecular mechanisms that determine lower expression in cultured cells. Xenobiotica 2002, 32:505-520.
47. Rosenfeld J.M., Vargas R., Xie W., Evans R.M. Genetic profiling defines the xenobiotic gene network controlled by the nuclear receptor pregnane X receptor. Mol. Endocrinol. 2003, 17:1268-1282.
48. Saini S.P., Sonoda J., Xu L., Toma D., Uppal H., Mu Y., Ren S., Moore D.D., Evans R.M., Xie W. A novel constitutive androstane receptor-mediated and CYP3A-independent pathway of bile acid detoxification. Mol. Pharmacol. 2004, 65:292-300.
49. Schmitz M.L., dos Santos Silva M.A., Baeuerle P.A. Transactivation domain 2 (TA2) of p65 NF-kappa B. Similarity to TA1 and phorbol ester-stimulated activity and phosphorylation in intact cells. J. Biol. Chem. 1995, 270:15576-15584.
50. Stanley L.A., Horsburgh B.C., Ross J., Scheer N., Wolf C.R. PXR and CAR: nuclear receptors which play a pivotal role in drug disposition and chemical toxicity. Drug Metab. Rev. 2006, 38:515-597.
51. Sueyoshi T., Kawamoto T., Zelko I., Honkakoski P., Negishi M. The repressed nuclear receptor CAR responds to phenobarbital in activating the human CYP2B6 gene. J. Biol. Chem. 1999, 274:6043-6046.
52. Sumida A., Fukuen S., Yamamoto I., Matsuda H., Naohara M., Azume J. Quantitative analysis of constitutive and inducible CYPs mRNA expression in the HepG2 cell line using reverse transcription-competetive PCR. Biochem. Biophys. Res. Commun. 2000, 267:756-760.
53. Synold T.W., Dussault I., Forman B.M. The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. Nat. Med. 2001, 7:584-590.
54. Taavitsainen, P., 2001. Cytochrome P450-isoform-specific in vitro methods to predict drug metabolism and interactions. Academic dissertation. Oulu University Press, ISBN 951-42-5900-9 (PDF).
55. Trubetskoy O., Marks B., Zielinski T., Yueh M.F., Raucy J. A simultaneous assessment of CYP3A4 metabolism and induction in the DPX-2 cell line. AAPS J. 2005, 7:6-13.
56. Truong N.T., Moncion A., Barouki R., Beaune P., de Waziers I. Regulatory sequence responsible for insulin destabilization of cytochrome P450 2B1 (CYP2B1) mRNA. Biochem. J. 2005, 388:227-235.
57. Turpeinen M., Uusitalo J., Jalonen J., Pelkonen O. Multiple P450 substrates in a single run: rapid and comprehensive in vitro interaction assay. Eur. J. Pharm. Sci. 2005, 24:123-132.
58. Vyhlidal C.A., Gaedigk R., Leeder J.S. Nuclear receptor expression in fetal and pediatric liver: correlation with CYP3A expression. Drug Metab. Dispos. 2006, 34:131-137.
59. Wang J., Pitarque M., Ingelman-Sundberg M. 3'-UTR polymorphism in the human CYP2A6 gene affects mRNA stability and enzyme expression. Biochem. Biophys. Res. Commun. 2006, 340:491-497.
60. Westerink W.M.A., Schoonen W.G.E.J. Cytochrome P450 enzyme levels in HepG2 cells and cryopreserved primary human hepatocytes and their induction in HepG2 cells. Toxicol. In Vitro 2007, 21:1581-1591.
61. Wienkers L.C., Heath T.G. Predicting in vivo drug interactions from in vitro drug discovery data. Nat. Rev. Drug Discov. 2005, 4:825-833.
62. Wilkening S., Bader A. Influence of culture time on the expression of drug-metabolizing enzymes in primary human hepatocytes and hepatoma cell line HepG2. J. Biochem. Mol. Toxicol. 2003, 17:207-213.
63. Wortham M., Czerwinski M., He L., Parkinson A., Wan Y.J. Expression of constitutive androstane receptor, hepatic nuclear factor 4α, and P450 oxidoreductase genes determines interindividual variability in basal expression and activity of a broad scope of xenobiotic metabolism genes in the human liver. Drug Metab. Dispos. 2007, 35:1700-1710.
64. Xu L., Glass C.K., Rosenfeld M.G. Coactivator and corepressor complexes in nuclear receptor function. Curr. Opin. Genet. Dev. 1999, 9:140-147.
65. Zelko I., Negishi M. Phenobarbital-elicited activation of nuclear receptor CAR in induction of cytochrome P450 genes. Biochem. Biophys. Res. Commun. 2000, 277:1-6.
66. Zhang B., Xie W., Krasowski M.D. PXR: a xenobiotic receptor of diverse function implicated in pharmacogenetics. Pharmacogenomics 2008, 9(11):1695-1709.
67. Zhu X.H., Wang C.-H., Tong Y.W. Growing tissue-like constructs with Hep3B/HepG2 liver cells on PHBV microspheres of different sizes. J. Biomed. Mater. Res. B. Appl. Biomater. 2006, 82:7-16.